Sarepta Therapeutics (SRPT) Gross Margin: 2012-2025
Historic Gross Margin for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to 77.49%.
- Sarepta Therapeutics' Gross Margin fell 1024.00% to 77.49% in Q2 2025 from the same period last year, while for Jun 2025 it was 80.44%, marking a year-over-year decrease of 784.00%. This contributed to the annual value of 83.22% for FY2024, which is 469.00% down from last year.
- Latest data reveals that Sarepta Therapeutics reported Gross Margin of 77.49% as of Q2 2025, which was down 22.51% from 100.00% recorded in Q1 2025.
- Sarepta Therapeutics' Gross Margin's 5-year high stood at 100.00% during Q1 2025, with a 5-year trough of 77.49% in Q2 2025.
- Over the past 3 years, Sarepta Therapeutics' median Gross Margin value was 87.33% (recorded in 2024), while the average stood at 86.41%.
- Examining YoY changes over the last 5 years, Sarepta Therapeutics' Gross Margin showed a top increase of 1,223bps in 2025 and a maximum decrease of 1,024bps in 2025.
- Quarterly analysis of 5 years shows Sarepta Therapeutics' Gross Margin stood at 84.24% in 2021, then soared by 384bps to 88.08% in 2022, then spiked by 78bps to 88.87% in 2023, then crashed by 896bps to 79.91% in 2024, then plummeted by 1,024bps to 77.49% in 2025.
- Its last three reported values are 77.49% in Q2 2025, 100.00% for Q1 2025, and 79.91% during Q4 2024.